The cancer mAbs market is one of the fastest-growing segments of the global pharmaceutical market. It has become a major research area for biotech and pharmaceutical companies due to the presence of high unmet medical needs in the market. Targeted therapies are revolutionizing the treatment methodologies of solid tumors and replacing existing chemotherapies. For instance, tumor-selective mAbs such as Avastin and Herceptin have transformed the cancer mAbs market. These agents addressed unmet clinical needs of the market, including reducing toxicity levels and increasing efficacy

PART 01: Executive summary

PART 02: Scope of the report

Market overview

Assumptions

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: mAbs: Overview

Evolution of mAb therapeutics

Conjugated cancer therapies using mAbs

PART 06: Timeline of mAbs for cancer

PART 07: Pipeline portfolio

List of Phase III pipeline molecules

List of Phase II pipeline molecules

List of Phase I pipeline molecules

PART 08: Market landscape

Market overview

Five forces analysis

PART 09: Market segmentation by type of mAbs

Naked mAbs

Conjugated mAbs

PART 10: Market segmentation by MOA

Immune system suppressors

Kill or inhibit malignant cells

Angiogenesis inhibitors

Radiation therapy to cancer cells

Delivering chemotherapy to cancer cells

PART 11: Geographical segmentation

Cancer mAbs market in Americas

Cancer mAbs market in EMEA

Cancer mAbs market in APAC

PART 12: Market drivers

Increase in demand for ADCs

Special regulatory drug designations

Advanced technological innovations

Increase in industry-academia collaborations

PART 13: Impact of drivers

PART 14: Market challenges

Complicated regulatory framework

Absence of adequate diagnosis and screening

procedures

High manufacturing costs coupled with stringent

regulations

Threat from chemotherapy and off-label drugs

PART 15: Impact of drivers and challenges

PART 16: Market trends

Emergence of targeted and combination therapies

Joint ventures and partnerships for R&D

Advent of biosimilars expected to improve the treatment

rates

PART 17: Vendor landscape

Competitive scenario

Key news

Other prominent vendors

PART 18: Key vendor analysis

Amgen

Bristol-Myers Squibb

F. Hoffmann-La Roche

Takeda Pharmaceuticals

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio